(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.08% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Gilead Sciences's revenue in 2025 is $28,754,000,000.On average, 6 Wall Street analysts forecast GILD's revenue for 2025 to be $35,506,502,426,188, with the lowest GILD revenue forecast at $35,322,308,271,542, and the highest GILD revenue forecast at $35,635,004,704,941. On average, 8 Wall Street analysts forecast GILD's revenue for 2026 to be $37,085,410,694,856, with the lowest GILD revenue forecast at $35,932,891,482,972, and the highest GILD revenue forecast at $39,706,613,840,808.
In 2027, GILD is forecast to generate $39,319,123,168,271 in revenue, with the lowest revenue forecast at $37,855,519,000,791 and the highest revenue forecast at $42,218,476,847,862.